News Search Results
Jan 09, 2025, 08:30 ET Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board
CITY, Jan. 9, 2025 /PRNewswire/ -- Cadenza Bio, Inc., a preclinical biotechnology company dedicated to developing small-molecule therapies for demyelinating and inflammatory disease, proudly announces the formation of its Women's
More news about: Cadenza Bio, Inc.
Jan 09, 2025, 08:05 ET Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation
More news about: Rigel Pharmaceuticals, Inc.
Jan 09, 2025, 08:05 ET Gene Therapy Pioneer Jim Wilson Comments on iECURE's Announcement of Complete Clinical Response for ECUR-506
gene engraftment in the dividing liver of the infant. We were able to advance our lead genome editing product into the clinic through iECURE, a biotechnology company that I founded in 2021. "We were highly encouraged by the preliminary report of the first OTCD infant that received our gene editing
More news about: GEMMA Biotherapeutics
Jan 09, 2025, 08:04 ET INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Jan 09, 2025, 08:01 ET RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing
significant impact on patients' lives." About RyboDyn RyboDyn, Inc., based in San Diego, CA, is a biotechnology company pioneering the development of first-in-class immunotherapies targeting the dark genome. By leveraging RyboCypher™, a proprietary
More news about: RyboDyn
Jan 09, 2025, 08:00 ET Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
aim to make a tangible difference for patients in areas of high unmet medical need." About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace®
More news about: Synaffix B.V.
Jan 09, 2025, 08:00 ET Deerfield Group Enhances Strategic Marketing, Communications Services for Biopharma, Health Tech Companies on West Coast
Deerfield Group is a full-service integrated marketing, advertising, and communications agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare
More news about: Deerfield Group
Jan 09, 2025, 08:00 ET Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
https://www.boehringer-ingelheim.com. About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace®
More news about: Synaffix B.V.
Jan 09, 2025, 07:51 ET Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
Jan 09, 2025, 07:45 ET Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
Jan. 9, 2025 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive interim safety and biomarker
More news about: Genascence
Jan 09, 2025, 07:05 ET RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
sclerosis, type 1 diabetes, and ankylosing spondylitis currently in development. About RheumaGen, Inc. RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA),
More news about: RheumaGen, Inc.
Jan 09, 2025, 07:00 ET Arkuda Therapeutics Announces Option Exercise and Asset Purchase
WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop medicines that change the trajectory of
More news about: Arkuda Therapeutics
Jan 09, 2025, 07:00 ET Nanoscope Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal
More news about: Nanoscope Therapeutics
Jan 09, 2025, 03:04 ET Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency
challenges faced by healthcare providers worldwide,"said Michael Lau, CEO at Anbio Biotechnology. About Anbio Biotechnology Anbio Biotechnology is a leading global medical device company specializing in in vitro diagnostics. Its diverse portfolio spans multiple
More news about: Anbio Biotechnology
Jan 09, 2025, 01:00 ET Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner
Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche
Jan 08, 2025, 16:01 ET AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jan 08, 2025, 14:27 ET DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
DIEGO, Jan. 8, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus
More news about: DIOSynVax
Jan 08, 2025, 14:21 ET DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
DIEGO, Jan. 8, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus
More news about: DIOSynVax
Jan 08, 2025, 12:00 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jan 08, 2025, 12:00 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
Jefferies downgraded Fortrea, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding. On this news, Fortrea's stock price fell $2.73 per share, or 12.29%, to close at $19.48
More news about: Pomerantz LLP
Jan 08, 2025, 10:30 ET Cell Therapy Technologies Market to Hit US$ 6.80 Billion by 2029 with 11.0% CAGR | MarketsandMarkets™
of this market. The end-user market is categorized into the biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks. The biopharmaceutical & biotechnology companies dominated the segment in 2023; the CROs & CMOs are likely to grow at a significant
More news about: MarketsandMarkets
Jan 08, 2025, 09:00 ET GlycoNex to Participate in Biotech Showcase 2025 During J.P. Morgan Week
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced its participation in Biotech Showcase 2025. The event
More news about: GlycoNex, Inc.
Jan 08, 2025, 08:05 ET Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president
More news about: Rigel Pharmaceuticals, Inc.
Jan 08, 2025, 08:01 ET Foundery Immune Studio, LLC Acquires Rights to a Suite of Next-Generation Clinical Stage Immunotherapies
FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- Foundery Immune Studio, LLC, a biotechnology venture studio focused on translating immunology discoveries into medicines, announced today its acquisition of worldwide rights for three clinical-stage
More news about: Foundery Immune Studio
Jan 08, 2025, 08:00 ET Sionna Therapeutics Announces the Appointment of Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors
product candidates in clinical development for the treatment of CF." Dr. Ruddy is the Chief Medical Officer of Tectonic Therapeutic, Inc., a biotechnology company focused on therapeutic proteins and antibodies that modulate G-protein coupled receptors. She also serves on the board of directors of Upstream
More news about: Sionna Therapeutics